**ESPERION**<sup>®</sup> REACHING GOAL

# Esperion Corporate Presentation

November 2024

### **Forward-looking Statements & Disclosures**

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion's commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.



### **Investment Highlights**

#### Attractive cardiovascular portfolio with significant growth opportunity

#### **Attractive market**

Large attractive cholesterol-lowering market with high unmet need



#### **Differentiated therapy**

The first non-statin LDL-C lowering therapy to demonstrate outcomes benefit in a combination of high-risk primary and secondary prevention patients



#### **Blockbuster potential**

-

Poised to help patients with established cardiovascular disease or at high risk for cardiovascular disease and not at their LDL-C goal despite being on a statin, or having tried a statin in the past

#### **Compelling pipeline**

Continuing to advance our allosteric platform for next generation ACLY with potential for broad therapeutic application; in pre-clinical stages

#### **Strong IP**

Composition of matter and/or market exclusivity coverage through mid-2031\* in major markets, providing opportunity for ample growth and value creation



#### **Experienced team**



Executive team, board of directors, and scientific advisory board all deeply entrenched in cardiovascular space

\* Pending pediatric exclusivity extension grant



### **Elevated Bad Cholesterol**

An established risk factor for cardiovascular disease

Causes more annual deaths than all forms of cancers combined<sup>1</sup>


Accounts for ~1 in 3 deaths in the U.S. and Europe <sup>1</sup>

CDC estimates heart disease deaths will increase 25% by 2030<sup>2</sup>

Studies show reducing LDL-C levels with lipid-lowering agents lowers incidence of ASCVD events <sup>3</sup>

Significantly less innovation versus other therapy areas <sup>4</sup>

**#1** Cause Of Death Worldwide



3. Ference BA, Ginsberg HN, Graham I, et al. *Eur Heart J.* 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144 4. Mckinsey & Co.



<sup>1.</sup> World Health Organization

<sup>2.</sup> CDC 2017-2030

### **New Labels Dramatically Increase Addressable Market**

New Label Total Addressable Market Opportunity

Patients not at LDL-C goal, in millions

**70M** 

+40M

### Untreated High-Risk Primary Prevention & ASCVD Patients

Primary prevention and not on a statin<sup>1,2,5,6</sup>



### Under-Treated High-Risk Primary Prevention & ASCVD Patients

15M high-risk primary prevention on a statin<sup>2,3,4</sup>
5M high-risk primary prevention and ASCVD, statin intolerant<sup>5</sup>

**10M** Original Label Feb. 2020

#### **Under-Treated ASCVD Patients<sup>1</sup>**

Secondary prevention population *and* on a maximally tolerated statin, not at LDL-C goal



Only LDL-C lowering non-statins to be indicated for primary prevention



Removes **statin use** qualifier from indication

#### **Original Label**

- HeFH or ASCVD
- On max tolerated statin
- Not at LDL-C goal

1. Allen JM, et al. Circulation. 2019;140:A12904. 2. Shen M, Nargesi AA, et al. J Am Heart Assoc. 2022;11:e026075. 3. Yang Y, et al. Circulation. 2021;144:A10434. 4. Wong ND, et al. J Clin Lipidology. 2016;10:1109-1118. 5. Bytyci I, et al. Eur Heart J. 2022;00:1-16. 6. Total U.S. Resident Population by Age, Sex, and Series: April 1, 2020 [table]; US Census Bureau: 2020.

**ESPERION** REACHING GOALS

# Introduced First Oral Non-statin LDL-C Lowering Therapy in 20 Years



#### **NEXLETOL®**

(bempedoic acid) Tablet is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for indicated patients



#### **NEXLIZET**®

(bempedoic acid and ezetimibe) Tablet is the first and only oral non-statin, LDL-C lowering combination medicine ever approved


NEXLETOL and NEXLIZET are each indicated as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. Important safety information can be found on slides 19 and 20. Full prescribing information can be found at: <a href="https://pi.esperion.com/nexletol/nexletol-pi.pdf">https://pi.esperion.com/nexletol/nexletol-pi.pdf</a> and <a href="https://pi.esperion.com/nexletol-pi.pdf">https://pi.esperion.com/nexletol/nexletol-pi.pdf</a> and <a href="https://pi.esperion.com/nexlizet/nexlizet-pi.pdf">https://pi.esperion.com/nexlizet/nexlizet/nexlizet-pi.pdf</a>

NEXLETOL and NEXLIZET available by prescription only. Known as NILEMDO<sup>®</sup> (bempedoic acid) & NUSTENDI<sup>®</sup> (bempedoic acid and ezetimibe) in Europe.

## **Addressing a Gap in Existing Therapy**

### Providing patients with an option <u>next</u> after statins

#### 70 million patients need additional LDL-C lowering <sup>1</sup>



**ESPERION** 

**REACHING GOALS** 

1. Refer to slide 5 for references.

2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003606/

3. Bruckert E, Hayem G, Dejager S, Yau C and Begaud B. Cardiovasc Drugs Ther. 2005;19:403-14.

### A Real Game Changer

New class of medicine, ATP citrate lyase inhibitor

~14,000 patients in 32 countries

Focused on significant, underserved population, including ~50% women

### Landmark CLEAR Outcomes Study



#### **Unprecedented CVOT**

#### Results published in NEJM

- MACE-4 reduction of 13%; MACE-3 reduction of 15%
- Myocardial infarction reduction of 23%; coronary revascularization reduction of 19%
- LDL-C reduction of 22%; hsCRP reduction of 22%
- First dedicated trial for statin intolerant patients
- 70% secondary prevention / 30% primary prevention

#### Primary prevention results published in JAMA

• MACE-4 reduction of 30%; MACE-3 reduction of 36%

### NEXLETOL: The only LDL-C lowering therapy since statins to reduce cardiovascular risk in both primary <u>and</u> secondary prevention populations


Note: please visit esperionscience.com for more information and links to journal publications.

 $\ensuremath{\mathbb{C}}$  2024 Esperion. All Rights Reserved – Do not copy or distribute.




# Strong Momentum in First Six Months of Launch, Steady Growth Continues Through Q3 2024

Quarterly Franchise RPE Trend



#### Weekly Franchise RPE Trend<sup>1</sup>




#### 1. Through September 30, 2024

Based on Symphony Data. RPE = Retail Prescription Equivalent; derived by normalizing the extended Rx units (number of tablets) to determine the 30-day supply equivalent.


#### **ESPERION**<sup>®</sup> REACHING GOALS

### **Great Strides Expanding International Reach**





### **Global Partnerships Expected to be Valuable Royalty Contributors**




**ESPERION** 

**REACHING GOALS** 

### **International Growth Continues at Strong Pace**

Cardiovascular risk reduction data and new market launches drive accelerating adoption



Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, the Netherlands.



## **Growing our Pipeline Beyond Bempedoic Acid**

Next-Generation ACL Inhibitor	Target	Discovery	Proof of Concept	Preclinical
Discovery of differentiated and highly potent allosteric ACL inhibitors with potential for broad therapeutic application. Potential optimization for different indications.	Hyperlipidemia & Cardiometabolic			
	Liver			
	Kidney			
	Oncology			
	Neurological Disorders			



## **Strong Intellectual Property**

#### Provides security for ample growth and value creation

- 100% U.S. and ROW Rights (outside of EU, Japan, and select countries in Asia, South/Latin America and Middle East) to NEXLETOL and NEXLIZET
- Composition of matter and/or market exclusivity coverage through mid-2031\* in major markets
- Life-cycle management opportunities to extend exclusivity both with NEXLETOL and NEXLIZET and future formulations
- Formulation, process manufacturing and methods of use pending applications may extend exclusivity through 2040, if issued

\* Pending pediatric exclusivity extension grant.



Composition of matter patent/IP coverage at least through mid-2031<sup>\*</sup> (with patent term extension) in the United States.



Composition of matter patent/IP coverage through at least 2028 (with patent term extension) in parallel with ten years of postapproval data exclusivity in Europe (i.e. February 2030).



Composition of matter patent/IP coverage through 2028 (with potential patent term extension). Eight years of post-approval data exclusivity in Japan is expected following anticipated regulatory approval in ~2025.

#### **ESPERION** REACHING GOALS

### **Esperion Leadership Team**

All with strong connections to our purpose







Eric Warren, R.Ph. Chief Commercial Officer



**ESPERION** 

**REACHING GOALS** 



### **Scientific Advisory Board**

#### **Renowned scientists to guide pipeline development**



Peter Libby, MD, FAHA Board Co-Chair, Brigham and Women's Hospital



Karin Bornfeldt, PhD, FAHA University of Washington



David Cohen, MD, PhD Brigham and Women's Hospital







Paul Ridker, MD Brigham and Women's Hospital

Massachusetts General Hospital

Jim Januzzi, MD



R. Preston Mason, MBA, PhD Brigham and Women's Hospital



Gerald Shulman, MD, PhD, MACP, MACE, FRCP Yale



16

Pradeep Natarajan, MD, MMsC Massachusetts General Hospital



# **THANK YOU**



# Important Safety Information



### **NEXLETOL®** Important Safety Information

- NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred.
- Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout
  treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms
  of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
- Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years
  of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue
  NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.
- The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in ≥2% of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.
- The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.
- Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL.
- Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

See full prescribing information <u>here</u>.



### **NEXLIZET®** Important Safety Information

- NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe or bempedoic acid.
- Hyperuricemia: Bempedoic acid, a component of NEXLIZET, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in
  treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated.
  Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
- Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more
  frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous
  tendon disorders. Discontinue NEXLIZET at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or
  tendon rupture.
- The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid (a component of NEXLIZET) in ≥2% of patients and greater than
  placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and
  elevated liver enzymes.
- Adverse reactions reported in ≥2% of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza.
- In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence ≥3% and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation.
- The most common adverse reactions in the cardiovascular outcomes trial of bempedoic acid (a component of NEXLIZET) at an incidence of ≥2% and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.
- Discontinue NEXLIZET when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious
  adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET.
- Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

#### See full prescribing information here.

#### **ESPERION**<sup>°</sup> REACHING GOALS